Rethinking COVID-19 in children: Lessons learned from pediatric viral and inflammatory cardiovascular diseases.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Energy Drink Exposures and Trends in Children and Young Adults Reported to the National Poison Data System.Progress in pediatric cardiology · 2025
   Article
2. Atrial fibrillation in a child with COVID-19 infection.Cardiology in the young · 2021
   Article
3. Disruption of healthcare: Will the COVID pandemic worsen non-COVID outcomes and disease outbreaks?Progress in pediatric cardiology · 2020
   Article
4. Syndrome resembling Kawasaki disease in COVID-19 asymptomatic children.Journal of infection and public health · 2020
   Review
5. COVID-19 in Pediatric Patients: A Focus on CHD Patients.Frontiers in cardiovascular medicine · 2020
   Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as